We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$1.39B
Cap. Flow %
-6.39%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Communication Services 8.41%
3 Technology 5.7%
4 Financials 3.99%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNA
76
AleAnna Inc
ANNA
$116M
$227K ﹤0.01%
78,400
– –
WELL icon
77
Welltower
WELL
$172B
$227K ﹤0.01%
1,000
-199,000
-100% -$42.1M
SLDPW icon
78
Solid Power Inc Warrant
SLDPW
$6.93M
$41.4K ﹤0.01%
405,316
– –
BGLWW
79
Blue Gold Ltd Warrant
BGLWW
$345K
$30.7K ﹤0.01%
255,800
-44,200
-15% -$9.51K
PACB icon
80
Pacific Biosciences
PACB
$420M
$23.9K ﹤0.01%
14,200
-120,800
-89% -$176K
GERN icon
81
Geron
GERN
$977M
$18.4K ﹤0.01%
14,400
-28,600
-67% -$40.3K
NVNIW
82
Nvni Group Limited Warrants
NVNIW
$17.6K ﹤0.01%
375,000
– –
CGC
83
Canopy Growth
CGC
$472M
$17.1K ﹤0.01%
18,000
-12,000
-40% -$12.7K
RANI icon
84
Rani Therapeutics
RANI
$102M
$15.7K ﹤0.01%
20,700
-57,300
-73% -$50.8K
BYND icon
85
Beyond Meat
BYND
$254M
$14.3K ﹤0.01%
633
– –
ADPT icon
86
Adaptive Biotechnologies
ADPT
$4.15B
– –
-11,000
Closed -$153K
AFRM icon
87
Affirm
AFRM
$25.8B
– –
-108,000
Closed -$4.95M
AIR icon
88
AAR Corp
AIR
$5.43B
– –
-46,000
Closed -$5.04M
ALKS icon
89
Alkermes
ALKS
$8.11B
– –
-20,800
Closed -$735K
ALT icon
90
Altimmune
ALT
$605M
– –
-27,600
Closed -$85K
AMKR icon
91
Amkor Technology
AMKR
$12.5B
– –
-104,000
Closed -$4.68M
APLS
92
DELISTED
Apellis Pharmaceuticals
APLS
– –
-6,000
Closed -$241K
ARDX icon
93
Ardelyx
ARDX
$1B
– –
-23,000
Closed -$138K
ARQT icon
94
Arcutis Biotherapeutics
ARQT
$3.15B
– –
-26,000
Closed -$613K
ARWR icon
95
Arrowhead Research
ARWR
$12.3B
– –
-15,800
Closed -$991K
AXSM icon
96
Axsome Therapeutics
AXSM
$10.9B
– –
-4,000
Closed -$676K
BCRX icon
97
BioCryst Pharmaceuticals
BCRX
$2.44B
– –
-24,000
Closed -$228K
BLTE
98
Belite Bio
BLTE
$6.49B
– –
-1,300
Closed -$207K
C icon
99
Citigroup
C
$221B
– –
-47,000
Closed -$5.33M
CAH icon
100
Cardinal Health
CAH
$53.4B
– –
-368,000
Closed -$77.8M
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2026 Portfolio in Review

As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
  • Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.